Torisel

RSS

temsirolimus

Authorised
This medicine is authorised for use in the European Union.

Overview

Torisel is a medicine used to treat patients with the following types of cancer:

  • advanced renal cell carcinoma (a kidney cancer). ‘Advanced’ means that the cancer has started to spread;
  • mantle cell lymphoma (a cancer of B cells, a type of white blood cell). Torisel is used in adults when the lymphoma has come back after previous treatment or if other treatments have not worked.

These diseases are rare, and Torisel was designated an ‘orphan medicine’ (a medicine used in rare diseases) on various dates.

Torisel contains the active substance temsirolimus.

This EPAR was last updated on 21/06/2022

Authorisation details

Product details
Name
Torisel
Agency product number
EMEA/H/C/000799
Active substance
Temsirolimus
International non-proprietary name (INN) or common name
temsirolimus
Therapeutic area (MeSH)
  • Carcinoma, Renal Cell
  • Lymphoma, Mantle-Cell
Anatomical therapeutic chemical (ATC) code
L01XE09
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
33
Date of issue of marketing authorisation valid throughout the European Union
19/11/2007
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

20/06/2022 Torisel - EMEA/H/C/000799 - IB/0087

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Renal-cell carcinoma

Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.

Mantle-cell lymphoma

Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
1 rating